Th9 and Th22 immune response in young patients with type 1 diabetes

Ryba-Stanisławowska, Monika; Werner, Paulina; Brandt, Agnieszka; Myśliwiec, Małgorzata; Myśliwska, Jolanta

doi:10.1007/s12026-015-8765-7

Cited by 26 publications

(18 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the present study, there was no statistical difference in Th22 frequency between MG patients and HCs, while a statistically significant decrease in Th22 was found post-TE. The role of Th22 cells in the pathogenesis of autoimmune diseases has been confirmed in many studies [16,[43][44][45][46][47].…”

Section: Discussionmentioning

confidence: 79%

High Frequency of Tc22 and Th22 Cells in Myasthenia Gravis Patients and Their Significant Reduction after Thymectomy

Robat-Jazi

Hosseini

Shaygannejad

et al. 2018

Neuroimmunomodulation

View full text Add to dashboard Cite

Objectives: Myasthenia gravis (MG) is an autoimmune disease accompanied by a thymic pathology and in most patients thymectomy (TE) is used as the therapeutic approach. Both B and T cells play an important role in MG pathogenesis. Methods: Twelve pre- and post-TE MG patients and 12 healthy controls (HCs) were enrolled. The mean percentages of Th22 and Tc22 cells were evaluated in MG patients (before and 6 months after TE) and HCs. Results: The mean percentage of Tc22 cells in pre-TE patients was significantly higher than in HCs (p < 0.05), and after TE Tc22 cells significantly decreased compared to pre-TE (p < 0.05). The frequency of Th22 cells in pre-TE MG patients was not significantly different from HCs, but after TE Th22 cells were significantly decreased compared to pre-TE (p < 0.05). Conclusion: Our findings suggest a possible role of Th22 and Tc22 in MG pathogenesis.

show abstract

Section: Discussionmentioning

confidence: 79%

High Frequency of Tc22 and Th22 Cells in Myasthenia Gravis Patients and Their Significant Reduction after Thymectomy

Robat-Jazi

Hosseini

Shaygannejad

et al. 2018

Neuroimmunomodulation

View full text Add to dashboard Cite

show abstract

“…IL‐5 is important for the proliferation of CD19 + IgM + B cells in NOD mice and stimulates the secretion of IL‐10 by B cells, which exerts a robust suppressive effect on the pathogenesis of diabetes . IL‐9 expression is increased in the serum of patients with T1D; it is correlated with the size of Th9 effector subpopulations and predicts HbA1c values, but the role of IL‐9 in T1D is uncertain . The IL‐4 and IL‐13 cytokines, encoded by adjacent genes, transduce signals via a partially shared receptor (IL‐4Rα), and their effects in T1D have been unveiled in a number of studies.…”

Section: Classical Cytokines With Anti‐inflammatory Rolesmentioning

confidence: 99%

“…13 IL-9 expression is increased in the serum of patients with T1D; it is correlated with the size of Th9 effector subpopulations and predicts HbA1c values, but the role of IL-9 in T1D is uncertain. 14,15 The IL-4 and IL-13 cytokines, encoded by adjacent genes, transduce signals via a partially shared receptor (IL-4Ra), and their effects in T1D have been unveiled in a number of studies.…”

Section: Type-2 Cytokinesmentioning

confidence: 99%

Cytokines in type 1 diabetes: mechanisms of action and immunotherapeutic targets

et al. 2020

View full text Add to dashboard Cite

Cytokines play crucial roles in orchestrating complex multicellular interactions between pancreatic β cells and immune cells in the development of type 1 diabetes (T1D) and are thus potential immunotherapeutic targets for this disorder. Cytokines that can induce regulatory functions—for example, IL‐10, TGF‐β and IL‐33—are thought to restore immune tolerance and prevent β‐cell damage. By contrast, cytokines such as IL‐6, IL‐17, IL‐21 and TNF, which promote the differentiation and function of diabetogenic immune cells, are thought to lead to T1D onset and progression. However, targeting these dysregulated cytokine networks does not always result in consistent effects because anti‐inflammatory or proinflammatory functions of cytokines, responsible for β‐cell destruction, are context dependent. In this review, we summarise the current knowledge on the involvement of well‐known cytokines in both the initiation and destruction phases of T1D and discuss advances in recently discovered roles of cytokines. Additionally, we emphasise the complexity and implications of cytokine modulation therapy and discuss the ways in which this strategy has been translated into clinical trials.

show abstract

“…In another study, it was also observed a link between Th22 and Th9 cells in DM1 patients. These patients showed an increase in Th9 and Th22 cells, as well as increased serum levels of IL-9 and IL-22 compared with healthy individuals [112].…”

Section: Based On Cytokines Profile and Effector Function Cd4 + T Hementioning

confidence: 82%

Cytokines and T Helper Cells in Diabetic Nephropathy Pathogenesis

Araújo¹,

Silva²,

Silva³

et al. 2016

JDM

View full text Add to dashboard Cite

Diabetic Nephropathy (DN) is considered the main cause of end stage kidney disease around the world. However, its pathogenesis is not completely established. More than just a direct consequence of chronic glycemic changes, recent studies had suggested Diabetic Nephropathy could be considered an inflammatory disease. It has been shown that concentrations of pro-inflammatory cytokines, as IL-1, IL-6, IL-18, IL-33, IFN-γ and TNF-α actively participate in development and progression of DN, and thus, are involved in pathogenesis. Besides, changes in acquired immune response, especially the presence of cellular immune response profiles of pro-inflammatory and effector nature, mainly Th1 and Th17, as the imbalance between interaction of cytokines and T regulatory cells, foment the onset and progression of DN. Here we summarize the main evidences that support the critical role of the immune system in this condition. These new conceptual advances in DN understanding are essential for development of new the rapeutical strategies and prognostic factors, which could be protagonists or adjuvants to the current ones, leading ultimately to a better clinical management of DN patients.

show abstract

Th9 and Th22 immune response in young patients with type 1 diabetes

Cited by 26 publications

References 23 publications

High Frequency of Tc22 and Th22 Cells in Myasthenia Gravis Patients and Their Significant Reduction after Thymectomy

High Frequency of Tc22 and Th22 Cells in Myasthenia Gravis Patients and Their Significant Reduction after Thymectomy

Cytokines in type 1 diabetes: mechanisms of action and immunotherapeutic targets

Cytokines and T Helper Cells in Diabetic Nephropathy Pathogenesis

Contact Info

Product

Resources

About